Navigation Links
Simcere Pharmaceutical Group Announces Extraordinary General Meeting of Shareholders
Date:11/19/2013

NANJING, China, Nov. 19, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, announced today that it has called an extraordinary general meeting of shareholders (the "EGM"), to be held on December 19, 2013 at 10:00 a.m. (Beijing Time). The meeting will be held at No. 699-18, Xuan Wu Avenue, Xuan Wu District, Nanjing, Jiangsu Province 210042, People's Republic of China, to consider and vote on, among other things, the proposal to authorize and approve the previously announced agreement and plan of merger (the "Merger Agreement") dated August 28, 2013 among the Company, Simcere Holding Limited and Simcere Acquisition Limited ("Merger Sub"), the plan of merger (the "Plan of Merger") and the transactions contemplated thereby.

Pursuant to the Merger Agreement, Merger Sub will merge with and into the Company, with the Company continuing as the surviving company. If completed, the merger will result in the Company becoming a privately-held company and its American Depositary Shares ("ADSs") will no longer be listed on the New York Stock Exchange and the American Depositary Shares program for the ADSs will terminate. The Company's board of directors, acting upon the unanimous recommendation of the special committee of the board of directors, authorized and approved the Merger Agreement, the Plan of Merger and the transactions contemplated thereby, and resolved to recommend that the Company's shareholders and ADS holders vote for, among other things, the proposal to authorize and approve the Merger Agreement, the Plan of Merger and the transactions contemplated thereby.

Shareholders of record as of the close of business in the Cayman Islands on December 9, 2013 will be entitled to vote at the EGM. The record date for ADS holders entitled to instruct The Bank of New York Mellon, the ADS depositary, to vote the shares represented by the ADSs is the close of business in New York City on November 18, 2013. Additional information regarding the EGM and the Merger Agreement can be found in the transaction statement on Schedule 13E-3, and the proxy statement attached as Exhibit (a)-(1) thereto, filed with the Securities and Exchange Commission (the "SEC"), which can be obtained from the SEC's website (http://www.sec.gov). INVESTORS AND SHAREHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THESE PROXY MATERIALS AND OTHER MATERIALS FILED WITH OR FURNISHED TO THE SEC, AS THEY CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE MERGER AND RELATED MATTERS.This announcement is neither a solicitation of proxies, an offer to purchase nor a solicitation of an offer to sell any securities and it is not a substitute for the proxy statement and other materials that have been or will be filed with or furnished to the SEC.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Safe Harbor StatementThis press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. These forward-looking statements can be identified by terminology such as "if," "will," "expected," and similar statements. Forward-looking statements involve inherent risks, uncertainties and assumptions. Risks, uncertainties and assumptions include: uncertainties as to how the Company's shareholders will vote at the meeting of shareholders; the possibility that competing offers will be made; the possibility that debt financing may not be available; the possibility that various closing conditions for the transaction may not be satisfied or waived; and other risks and uncertainties discussed in documents filed with the SEC by the Company, as well as the Schedule 13E-3 transaction statement and the proxy statement to be filed by the Company. These forward-looking statements reflect the Company's expectations as of the date of this press release. You should not rely upon these forward-looking statements as predictions of future events. Simcere does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Investor and Media Contacts: Email: ir@simcere.comIn Nanjing:In the United States:Vivien Liang

Cindy Zheng Simcere Pharmaceutical Group

Brunswick Group LLCTel: 86-25-8556-6666 x 8857

Tel: 1-212-333-3810In Beijing:Yue YuBrunswick Group Tel: 86-10-5960-8600
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2013 Results
2. Simcere Pharmaceutical Group to Announce Third Quarter 2013 Financial Results on Thursday, November 14, 2013
3. Simcere Pharmaceutical Group Enters Into Definitive Merger Agreement for Going Private Transaction
4. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2013 Results
5. Simcere Pharmaceutical Group to Announce Second Quarter 2013 Financial Results on Tuesday, August 13, 2013
6. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Boda
7. Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China
8. Simcere Pharmaceutical Group Announces Resignation of Chief Scientific Officer
9. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2013 Results
10. Simcere Pharmaceutical Group Filed 2012 Annual Report on Form 20-F
11. Simcere Pharmaceutical Group to Announce First Quarter 2013 Financial Results on Thursday, May 9, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017  PhaseRx, Inc. (NASDAQ: ... life-threatening inherited liver diseases in children, today reported ... year ended December 31, 2016 and provided an ... "PhaseRx continued to make progress during the fourth ... results from our non-human primate safety study, and with ...
(Date:3/24/2017)... , Mar 24, 2017 Research and ... Manufacturing Market, 2017-2027" report to their offering. ... The Cell Therapy ... rapidly growing market of cell therapy manufacturing and focuses both ... facilities. These therapies are anticipated to emerge as viable alternatives ...
(Date:3/24/2017)... March 24, 2017  Zymo Research Corp., ... Hamilton Robotics, Inc., who designs, manufactures and ... collaboration that teams Zymo Research,s DNA methylation ... DNA extraction products with Hamilton,s high-throughput automation ... methods for microbiomics and RNA isolation for ...
Breaking Medicine Technology:
(Date:3/27/2017)... , ... March 27, 2017 , ... ... comprehensive weight management program at Women’s Excellence will help patients lose weight and ... physical exam. The specialists at Women's Excellence will measure BMI, body fat ...
(Date:3/27/2017)... ... 2017 , ... Janet Schloz is still in shock after receiving a $2,500 Academic Award from ... long time,” she said. , She thinks the coming week is going to be a ... would have to help my students.” , The award will allow the 4th grade teacher ...
(Date:3/27/2017)... ... March 27, 2017 , ... ?Grow Healthy Vending ... the pending litigation between itself and 1800 Vending DBA Healthy You Vending. (Civil ... am thrilled to announce that we have now reached a settlement agreement regarding ...
(Date:3/26/2017)... Columbus, Ohio (PRWEB) , ... March 26, 2017 ... ... 100 doctors worldwide to receive the RealSelf 100 Award, a prestigious award honoring ... elective cosmetic procedures and to find and connect with doctors and clinics. , ...
(Date:3/24/2017)... ... 24, 2017 , ... Mediaplanet today announces distribution of its ... obstacles facing infection prevention and offer strategies for the health care community to ... , The print component of “Fighting Infection” is distributed within the Friday, March ...
Breaking Medicine News(10 mins):